Philikos announces initiation of clinical Phase 1/2 study with T-Guard® in patients with systemic sclerosisNIJMEGEN, the Netherlands, May 20, 2025 (GLOBE NEWSWIRE) -- Philikos B.V., a Dutch ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 7% in the afternoon session after the FDA ...

By Nana Yaw Reuben Jr.The Open Forum on Agricultural Biotechnology in Africa a non-governmental organization fostering ...

Following President Trump's Most Favored Nation executive order, HHS and CMS have released the target price for pharmaceutical manufacturers to meet.

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...

Cell division is an essential biological process that removes aged cells and continuously renews tissues. In the human body, billions of cells divide each day: intestinal cells are completely renewed ...

In March, 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan.

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

The only gene-editing therapy currently on the market is a CRISPR–Cas9-based treatment for two blood disorders, sickle-cell ...